Science Explorer Back to mapMap
Discussion
Institution · Bologna · Italy

Italian Sarcoma Group

italiansarcomagroup.orgROR OpenAlex
Research works
12
▼ 91% vs 2018-21
Citations
92
8.0 per fractional work
Top-10% rate
11.8%
all institutions 10.0%
Open access
23%
world 40%
International
21%
world 18%
Italian Sarcoma Group

Not ranked overall: Italian Sarcoma Group is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Italian Sarcoma Group work in?

In all years, 90% of research at Italian Sarcoma Group is in Health Sciences, 5% in Life Sciences. Its largest fields are Medicine (88%), Biochemistry, Genetics and Molecular Biology (4%), Economics, Econometrics and Finance (3%). It does 2.4× the world's share of Health Sciences.

Health Sciences: 10 fractional works · 89.9% of its workMedicine: 10 fractional works · 87.9% of its workPulmonary and Respiratory Medicine: 4 fractional works · 31.3% of its workRheumatology: 2 fractional works · 15.4% of its workOncology: 1 fractional works · 11.0% of its workPathology and Forensic Medicine: 1 fractional works · 7.9% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 3.6% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 3.5% of its workGastroenterology: 0 fractional works · 3.2% of its workSurgery: 0 fractional works · 2.9% of its workNeurology: 0 fractional works · 2.8% of its workEmergency Medicine: 0 fractional works · 1.5% of its workOrthopedics and Sports Medicine: 0 fractional works · 1.5% of its workPhysiology: 0 fractional works · 1.2% of its workHealth Informatics: 0 fractional works · 0.6% of its workRadiology, Nuclear Medicine and Imaging: 0 fractional works · 0.6% of its workGenetics: 0 fractional works · 0.4% of its workEpidemiology: 0 fractional works · 0.3% of its workPediatrics, Perinatology and Child Health: 0 fractional works · 0.3% of its workDentistry: 0 fractional works · 2.0% of its workOral Surgery: 0 fractional works · 2.0% of its workLife Sciences: 1 fractional works · 5.2% of its workBiochemistry, Genetics and Molecular Biology: 0 fractional works · 4.1% of its workCancer Research: 0 fractional works · 3.6% of its workMolecular Biology: 0 fractional works · 0.5% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 0.7% of its workToxicology: 0 fractional works · 0.7% of its workImmunology and Microbiology: 0 fractional works · 0.4% of its workImmunology: 0 fractional works · 0.4% of its workSocial Sciences: 0 fractional works · 3.7% of its workEconomics, Econometrics and Finance: 0 fractional works · 3.3% of its workEconomics and Econometrics: 0 fractional works · 3.3% of its workDecision Sciences: 0 fractional works · 0.4% of its workStatistics, Probability and Uncertainty: 0 fractional works · 0.4% of its workPhysical Sciences: 0 fractional works · 1.1% of its workMathematics: 0 fractional works · 1.0% of its workStatistics and Probability: 0 fractional works · 1.0% of its workChemistry: 0 fractional works · 0.2% of its workALL ITS WORKItalian SarcomaGroup12fractional works, all years
Life Sciences5%Physical Sciences1%Health Sciences90%Social Sciences4%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 9 fields, with their numbers
    1. Medicine1087.9%
    2. Dentistry02.0%
    1. Biochemistry, Genetics and Molecular Biology04.1%
    2. Pharmacology, Toxicology and Pharmaceutics00.7%
    3. Immunology and Microbiology00.4%
    1. Economics, Econometrics and Finance03.3%
    2. Decision Sciences00.4%
    1. Mathematics01.0%
    2. Chemistry00.2%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

What are the most cited papers from Italian Sarcoma Group?

The most cited paper from Italian Sarcoma Group is "Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups" (Alessandro Gronchi et al., 2020), with 264 citations. Next come "Neoadjuvant chemotherapy in high‐risk soft tissue sarcomas: A Sarculator‐based risk stratification analysis of the ISG‐STS 1001 randomized trial" (108) and "Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group" (96).

Most cited papers
#PaperReleasedCitations
1 Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups Alessandro Gronchi et al. · Journal of Clinical Oncology Open access 18 May 2020 264
2 Neoadjuvant chemotherapy in high‐risk soft tissue sarcomas: A Sarculator‐based risk stratification analysis of the ISG‐STS 1001 randomized trial Sandro Pasquali et al. · Cancer Open access 13 Oct 2021 108
3 Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group Giovanni Grignani et al. · The Lancet Oncology Open access 11 Sep 2018 96
4 Parosteal osteosarcoma: a monocentric retrospective analysis of 195 patients Poosit Ruengwanichayakun, Marco Gambarotti, Tommaso Frisoni et al. · Human Pathology 23 May 2019 41
5 High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series Emanuela Palmerini, Elisabetta Setola, Giovanni Grignani et al. · Cells Open access 31 Oct 2020 36
All 38 most cited papers, with filters and sorting

Which research topics does Italian Sarcoma Group publish most on?

By volume in 2022-now: Bone Tumor Diagnosis and Treatments, Cancer Genomics and Diagnostics, Pharmacovigilance and Adverse Drug Reactions and Ethics in Clinical Research.

Bone Tumor Diagnosis and…0Bone Tumor Diagnosis and Treatments: 0 fractional worksCancer Genomics and Diag…0Cancer Genomics and Diagnostics: 0 fractional worksPharmacovigilance and Ad…0Pharmacovigilance and Adverse Drug Reactions: 0 fractional worksEthics in Clinical Resea…0Ethics in Clinical Research: 0 fractional worksSarcoma Diagnosis and Tr…0Sarcoma Diagnosis and Treatment: 0 fractional worksBiomedical Ethics and Re…0Biomedical Ethics and Regulation: 0 fractional worksSoft tissue tumor case studies: 0 fractional works
RheumatologyCancer ResearchToxicologyPublic Health, Environmental and Occupational Health2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Bone Tumor Diagnosis and Treatments Rheumatology 0 works
  2. 2 Cancer Genomics and Diagnostics Cancer Research 0 works
  3. 3 Pharmacovigilance and Adverse Drug Reactions Toxicology 0 works
  4. 4 Ethics in Clinical Research Public Health, Environmental and Occupational Health 0 works
  5. 5 Sarcoma Diagnosis and Treatment Pulmonary and Respiratory Medicine 0 works
  6. 6 Biomedical Ethics and Regulation Physiology 0 works
  7. 7 Soft tissue tumor case studies Rheumatology 0 works
  8. 8 Oral and Maxillofacial Pathology Oral Surgery 0 works
  9. 9 Soft tissue tumors and treatment Pathology and Forensic Medicine 0 works
  10. 10 Musculoskeletal synovial abnormalities and treatments Rheumatology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available23.0%not open77.0%

World: 40% of research is openly available.

with international co-authors21.3%domestic only78.7%

World: 18% is written across borders.

How has Italian Sarcoma Group's research output changed?

Output in 2022-2025 was 91% lower than in 2018-2021.

still counting2010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Italian Sarcoma Group as a percentage of every work published that year, 0.0000033% in 2023.

still counting0.000050%0.00010%Italian Sarcoma Group0.0000043% in 202520102020

Fractional works of Italian Sarcoma Group over all fractional works that year. How the balance of science has shifted.

Other research institutions in Bologna

All research institutions in Bologna

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Italian Sarcoma Group. Posts are plain text and can be reported.